A gain-of-function mutation in ATP6V0A4 drives primary distal renal tubular alkalosis with enhanced V-ATPase activity.

Si-Qi Peng, Xiao-Liang Zhang, Ting-Song Li, Cheng-Kun Wang, Jia-Xuan Sun, Zhi-Yuan Wei, Xiao-Xu Wang, Jun-Lan Yang, Jin-Xuan Wei, Rui-Ning Zhou, Wan-Yi Wang, Wen Shi, Yi-Lin Zhang, Hong Fan, Yan Yang, Xin-Hua Li, Hui Cai, Bin Wang, Jun Liao, Lu Huang, Qian-Qian Wu, Bi-Cheng Liu

Journal: The Journal of clinical investigation 2025;135(13):

PMID: 40299568

Abstract

The ATP6V0A4 gene encodes the a4 subunit of vacuolar H+-ATPase (V-ATPase), which mediates hydrogen ion transport across the membrane. Previous studies have suggested that mutations in ATP6V0A4 consistently result in a loss of function, impairing the hydrogen ion transport efficacy of V-ATPase and leading to distal renal tubular acidosis and sensorineural hearing loss. Here, we identified a 32-year-old male patient and his father, both of whom harbored a heterozygous ATP6V0A4 p.V512L mutation and exhibited hypochloremic metabolic alkalosis, acidic urine, and hypokalemia. Through a series of protein structural analyses and functional experiments, the V512L mutation was confirmed as a gain-of-function mutation in the ATP6V0A4 gene. V512-a4 increased a4 subunit expression abundance by enhancing V512L-a4 stability and reducing its degradation, which in turn potentiated the capacity of V-ATPase to acidify the tubular lumen, leading to acidic urine and metabolic alkalosis. Through mutant V512L-a4 subunit structure-based virtual and experimental screening, we identified F351 (C25H26FN3O2S), a small-molecule inhibitor specifically targeting the V512L-a4 mutant. In conclusion, we identified a gain-of-function mutation in the ATP6V0A4 gene, broadening its phenotypic and mutational spectrum, and we provide valuable insights into potential therapeutic approaches for diseases associated with ATP6V0A4 mutations.

Address: Department of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, China.; Department of Physiology, School of Basic Medical Science, Nanjing Medical University, Nanjing, China.; Nanjing Jiangbei New Area Biopharmaceutical Public Service Platform Co. Ltd, Nanjing, China.; School of Science, China Pharmaceutical University, Jiangning District, Nanjing, China.; Department of Medical Genetics and Developmental Biology, Medical School of Southeast University, The Key Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Southeast University, Nanjing, China.; Division of Renal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.; Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.; Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.